Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05513001 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
A Phase 3 study of Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
- 20
- Study locations
NCT05513001 is a Phase 3 study of Chronic Spontaneous Urticaria that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 696 participants, below the 1,388-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05513001, a Phase 3 study of Chronic Spontaneous Urticaria, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LOU064 (blinded)
- DRUG LOU064 (open label)
Study Locations (20)
Florida
- Florida Ctr Allergy Asthma Research - Aventura
- Finlay Medical Research - Greenacres City
- Miami Dade Medical Research - Miami
- Sarasota Clinical Research - Sarasota
- Allergy and Asthma Diagnostic Treatment Center - Tallahassee
California
- Kern Research - Bakersfield
- Antelope Valley Clinical Trials - Lancaster
- Allergy and Asthma Consultants - Redwood City
Alabama
- Allervie Clinical Research - Birmingham
- Cahaba Derm and skin hlth ctr 27 - Birmingham
Arkansas
- Acuro Research Inc - Little Rock
- Arkansas Research Trials - North Little Rock
Colorado
- Asthma and Allergy Associates P C - Colorado Springs
- Colorado Allergy and Asthma Ctr PC - Denver
Illinois
- Endeavor Health - Glenview
- Asthma and Allergy Center of Chicago S C - River Forest
Arizona
- Research Solutions of Arizona - Litchfield Park
Connecticut
- UCONN Health Dermatology - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2022-12-09 |
| Est. Completion | 2027-08-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05513001
The ClinicalTrials.gov registry entry for NCT05513001 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 696 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,388-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (50% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05513001 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05513001 about?
NCT05513001 is a clinical study titled "An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib". The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study wil...
What is the current status of trial NCT05513001?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2022-12-09. Estimated completion is 2027-08-02.
What conditions does trial NCT05513001 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.
What interventions are being tested in trial NCT05513001?
The interventions under investigation include: Placebo (DRUG), LOU064 (blinded) (DRUG), LOU064 (open label) (DRUG).
Who is sponsoring clinical trial NCT05513001?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05513001 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
RECRUITING · Phase 3
-
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
RECRUITING · Phase 3
-
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
ACTIVE NOT RECRUITING · Phase 3
-
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
COMPLETED · Phase 3
-
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.